

SECRETARY OF THE SENATE
00 DEC -5 PM 2:02

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Duberstein Group, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported Suite 500 Washington 2100 Pennsylvania Avenue, NW DC 20037 USA			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name John W. Angus, III		Telephone 202-728-1100	5. Senate ID # 12675-253
7. Client Name <input type="checkbox"/> Self Pharmacia & Upjohn, Inc.		6. House ID # 31811024	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$20,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____ Date 12/04/2000

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 1 of 5

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia & Upjohn, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific Lobbying issues
S.2099, Genetically Engineered Food Right-to-Know Act, Genetically modified organisms
H.R.3377, Genetically Engineered Food Right to Know Act, Genetically modified organisms

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Angus, III, John W.</u>		<u>No</u>
<u>Berman, Michael S.</u>		<u>No</u>
<u>Champlin, Steven M.</u>		<u>No</u>
<u>Duberstein, Kenneth M.</u>		<u>No</u>
<u>Gandy, Henry M.</u>		<u>No</u>
<u>Meyer, Daniel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 12/04/1900

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 2 of 5

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia & Upjohn, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

- S.2753, Medicare Expansion for Needed Drugs (MEND) Act of 2000, Medicare prescription drug benefit
- H.R.2782, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, Medicare prescription drug benefit
- H.R.2927, Affordable Prescription Drugs Act, Medicare prescription drug benefit
- H.R.4607, Medicare Prescription Drug Act of 2000, Medicare prescription drug benefit
- H.R.4577, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Medicare prescription drug benefit
- S.2553, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Medicare prescription drug benefit
- S.2758, Medicare Outpatient Drug Act of 2000, Medicare prescription drug benefit
- H.R.1109, Medicare Outpatient Prescription Drug Coverage Act of 1999, Medicare prescription drug benefit
- H.R.2012, Medicare Prescription Drug Benefit Act of 1999, Medicare prescription drug benefit

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate
The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Angus, III, John W.		No
Berman, Michael S.		No
Champlin, Steven M.		No
Duberstein, Kenneth M.		No
Gandy, Henry M.		No
Meyer, Daniel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 12/04/1900

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 3 of 5

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia & Upjohn, Inc.

Item	Description	Data
16	Lobbying Issues	H.R.664, Prescription Drug Fairness for Seniors Act of 1999, Medicare prescription drug benefit
16	Lobbying Issues	H.R.1495, Access to Prescription Medications in Medicare Act of 1999, Medicare prescription drug benefit
16	Lobbying Issues	S.731, Prescription Drug Fairness for Seniors Act of 1999, Medicare prescription drug benefit
16	Lobbying Issues	S.841, Access to Rx Medications in Medicare Act of 1999, Medicare prescription drug benefit
16	Lobbying Issues	H.R.4680, Medicare Rx 2000 Act, Medicare prescription drug benefit
16	Lobbying Issues	

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia & Upjohn, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues


- S.1191, International Prescription Drug Parity Act, Drug pricing
- S.2466, To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs, Drug pricing
- S.2465, Prescription Price Equity Act of 2000, Drug pricing
- S.2464, Prescription Drug Fairness Act, Drug pricing

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Angus, III, John W.</u>		<u>No</u>
<u>Berman, Michael S.</u>		<u>No</u>
<u>Champlin, Steven M.</u>		<u>No</u>
<u>Duberstein, Kenneth M.</u>		<u>No</u>
<u>Meyer, Daniel</u>		<u>No</u>
<u>Gandy, Henry M.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 12/04/1900

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 5 of 5